CRIS Current Research Information System

CATTINA, FEDERICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.524
EU - Europa 1.965
AS - Asia 1.764
AF - Africa 164
SA - Sud America 117
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.541
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.499
GB - Regno Unito 594
SG - Singapore 593
CN - Cina 549
SE - Svezia 356
DE - Germania 252
VN - Vietnam 226
HK - Hong Kong 183
IT - Italia 182
IN - India 119
RU - Federazione Russa 113
FR - Francia 98
BR - Brasile 80
IE - Irlanda 77
NL - Olanda 66
CH - Svizzera 56
ZA - Sudafrica 55
TG - Togo 44
EE - Estonia 42
NG - Nigeria 37
UA - Ucraina 29
FI - Finlandia 24
AR - Argentina 22
BG - Bulgaria 18
JO - Giordania 18
CA - Canada 17
CI - Costa d'Avorio 17
GR - Grecia 17
IR - Iran 17
BE - Belgio 16
JP - Giappone 12
KR - Corea 11
AT - Austria 7
MX - Messico 7
TR - Turchia 7
ID - Indonesia 6
AU - Australia 5
CL - Cile 5
ES - Italia 5
LB - Libano 5
PL - Polonia 5
IQ - Iraq 4
KZ - Kazakistan 4
SC - Seychelles 4
CZ - Repubblica Ceca 3
EC - Ecuador 3
BD - Bangladesh 2
CO - Colombia 2
EG - Egitto 2
GY - Guiana 2
MA - Marocco 2
TW - Taiwan 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
DZ - Algeria 1
EU - Europa 1
MK - Macedonia 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 6.541
Salva come PNG Salva come JPEG
Città #
Southend 549
Singapore 379
Chandler 288
Ashburn 268
Fairfield 230
Hong Kong 179
Beijing 138
Houston 134
Ann Arbor 129
Seattle 120
Wilmington 119
Woodbridge 112
Princeton 110
Santa Clara 93
Dublin 77
Dong Ket 76
Cambridge 74
Boardman 63
Bern 51
Nanjing 51
Westminster 50
Padova 49
Lomé 44
Medford 41
Bologna 38
Ho Chi Minh City 38
Los Angeles 34
New York 30
Hebei 25
Abeokuta 24
Hanoi 24
Hefei 24
Jinan 24
Shenyang 24
Saint Petersburg 23
Nanchang 20
Redondo Beach 20
Amman 18
Berlin 18
Changsha 18
Helsinki 18
San Diego 18
Sofia 18
Abidjan 17
São Paulo 17
Bremen 16
Brussels 16
Florence 16
Frankfurt am Main 15
Turin 13
Dallas 12
Falls Church 12
Tianjin 12
Buffalo 11
Guangzhou 11
Shanghai 11
Tokyo 11
Ningbo 10
Jiaxing 9
Munich 9
Norwalk 9
Hangzhou 8
Mountain View 8
Redwood City 8
London 7
Seoul 7
Toronto 7
Brooklyn 6
Dearborn 6
Düsseldorf 6
Fuzhou 6
Johannesburg 6
Las Vegas 6
Lauterbourg 6
Paris 6
Tehran 6
Haikou 5
Haiphong 5
Hyderabad 5
Hải Dương 5
Kunming 5
Lanzhou 5
Mashhad 5
Milan 5
Mülheim 5
Roubaix 5
Taiyuan 5
Taizhou 5
Turku 5
Yubileyny 5
Zhengzhou 5
Da Nang 4
Farra d'Isonzo 4
Grafing 4
Jakarta 4
Mumbai 4
Nuremberg 4
Olalla 4
Orem 4
Phoenix 4
Totale 4.317
Salva come PNG Salva come JPEG
Nome #
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 227
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 204
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 199
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 196
RALE051: a novel established cell line of sporadic Burkitt lymphoma 179
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 174
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 173
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 173
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 171
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 164
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 160
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 155
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 152
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 150
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 146
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 144
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 141
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 140
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 138
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 138
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 138
Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells) 136
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 135
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 132
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 131
Tp53 mutation screening in adult acute myeloid leukemia (AML) patients shows a strong association with complex karyotype and poor outcome 130
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 128
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin 128
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 124
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 124
LOSS OF CDKN2A GENE IS A POOR PROGNOSTIC MARKER IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS 123
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 123
PF-04449913 Reverts Multi Drug Resistance (MDR) by a Strong Down-Regulation of ABCA2 and BCL2 on Leukemia Stem Cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia Treated Patients 123
NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING TECHNOLOGY REVEALS NOVEL COMMON GENETIC ALTERATIONS IN THE HEDGEHOG PATHWAY IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 122
MULTIPLEX PCR TO RAPIDLY IDENTIFY IKZF1 (IKAROS) GENE BREAKPOINTS IN BCRABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 122
The Small Molecule CHK1/CHK2 Inhibitor PF-0477736 (Pfizer) Demonstrates Single Agent Activity and Synergizes with Chemotherapy in Diffuse Large B-Cell Lymphoma 122
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 119
The role of the loss of CDKN2A gene on prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia (ALL) 119
SEVERAL FUSION TRANSCRIPTS ARE DETECTED BY NEXT GENERATION PAIRED END TRANSCRIPTOMIC RE-SEQUENCING APPROACH IN ADULT BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 115
PF-04449913 reverts multi drug resistance (MDR) by a strong down-regulation of ABCA2 and BCL2 on leukemia stem cells in phase I acute myeloid leukemia and chronic myeloid leukemia treated patients 115
Ultra-Deep Sequencing Strategy Is a Precious Tool to Find Small Clones Harbouring FLT3 Mutations in AML Patients 114
Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain Allows Earlier Detection and More Accurate Characterization of Resistant Subclones in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Receiving Tyrosine Kinase Inhibitor-Based Therapies 114
Molecular characterization of TP53 mutations in B-acute lymphoblastic leukemia (B-ALL) reveals missense substitutions, aberrant exon-junctions and intron retention events 105
SET-UP OF A MULTIPLEX PCR TO RAPIDLY DETECT IKZF1 (IKAROS) GENE BREAKPOINT DELETION IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 104
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 96
Loss of the tumor suppressor genes CDKN2A/ARF impairs prognosis in adult BCR-ABL1 positive acute lymphoblastic leukemia (ALL) 83
PROSPECTIVE PHASE II STUDY ON LOW-DOSE 5-AZACYTIDINE FOR TREATMENT OF SYMPTOMATIC PATIENTS WITH LOW/INT-1 RISK MYELODISPLASIA 56
Totale 6.663
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.793
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.793
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021392 0 0 0 0 0 21 17 39 54 35 43 183
2021/2022912 64 13 64 67 106 69 13 48 46 78 156 188
2022/20231.177 168 190 42 156 85 89 31 75 160 14 81 86
2023/2024269 13 49 8 30 16 56 19 16 19 12 11 20
2024/2025981 55 170 88 70 152 35 59 12 13 106 14 207
2025/20261.000 154 151 169 125 280 121 0 0 0 0 0 0
Totale 6.663